Solventum Corporation SOLV
Composite 55/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 26/100 — a moderate mark against it.
Momentum ranks 77/100 — a strong point in its favour. Valuation ranks 61/100 — a slight point in its favour. Growth ranks 60/100 — a slight point in its favour.
Balance-sheet strength ranks 26/100 — a moderate mark against it.
What the company does Solventum Corporation (SOLV) is a diversified healthcare company with three segments: Medsurg (wound care, surgical supplies), Dental Solutions (orthodontic and restorative products), and Health Information Systems (software for healthcare documentation and billing).
Key financials Revenue growth is modest at 0.9%, but net margin stands at 17.3% and ROE at 34.0%. Operating margin is 9.8%, with gross margin at 54.8%. Debt/Equity is 1.10 and net debt/EBITDA is 4.29; current ratio is 1.02.
Stock health Sideravia scores Quality 59.8, Growth 59.5, Momentum 71.4, and Valuation 59.7, with an overall 54.1. Momentum is strong: 12-month return 26.74%, RSI(14) 66.80.
Price vs fair value The stock trades at a discount of 2.90% versus the analyst mean target of 93.92. - Healthcare Stock for Long-Term Investors (StockStory) highlights SOLV as a long-term pick, supporting positive sentiment. - Recent 1-day gain of 1.88% aligns with upward momentum. - Discount to target suggests room for convergence as fundamentals stabilize.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.